While the challenges continue to be daunting, there are numerous signs of progress in the fight to eradicate HIV by 2030.
Between 2012 and 2016, new infections in New York City decreased by 26 percent. In 2017, new infections in San Francisco fell to a record low of 221 in the city that was once known as ground zero for the AIDS epidemic. While we still have a long way to go, each of these headlines would have been unthinkable 24 years ago.
Dining Out For Life®, Hosted by Subaru of America, Set for Thursday, April 25th
PHILADELPHIA, March 19, 2019 /3BL Media/ – Dining Out For Life® hosted by Subaru of America is an annual dining fundraising event raising money for community-based organizations serving people living with or impacted by HIV.
The concept is simple: Restaurants donate a generous percentage of their sales to a local HIV service organization, and Dining Out For Life helps to fill participating restaurants with diners. Find a restaurant from the list of participating locations and on that city’s event date, Dine Out to help end HIV!
In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who's hard at work on the holy grail of HIV research: a preventive treatment.
By Sheila Weller
In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, Global Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines & Prevention B.V., was devoted to learning as much as she could about the disease—and saw her role as that of a researcher, rather than someone who closely interacted with people who were living with HIV.
Preventative HIV innovations. Better access to oncology care. A mobile messaging service for moms. These are just a few of the initiatives underway—and Chairman and CEO Alex Gorsky sits down for an exclusive interview about all of them.
Johnson & Johnson first opened its doors in South Africa in 1930, and in the nearly 90 years since, the company has remained committed to helping address unmet global public health needs that have impacted the country and the region as a whole.
This year, Gilead sponsored @aidswalksf, the largest #AIDS fundraising event in Northern California. 10,000 people participated in the 10k walk, and raised more than $1.8 million to benefit HIV/AIDS support organizations in the Bay Area.
In the past two decades, incredible progress has been made in the fight against HIV in the United States. Through a steady stream of innovation, more people living with HIV are leading longer, healthier lives. But the work is far from over. According to the CDC, as of 2014, 45 percent of people living with HIV in the U.S. are now 50 years old or older, and by 2020 that percentage is estimated to reach 70 percent.
New Initiative Mobilizes Local Communities to Implement Solutions
FOSTER CITY, Calif., Dec. 4, 2017 /3BL Media/ -- Gilead Sciences, Inc.(NASDAQ:GILD) today announced the launch of the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
FOSTER CITY, Calif., May 2, 2018 /3BL Media/ — Gilead Sciences, Inc. today announced the release of its 2017 Year in Review, composed of its Annual Report and Corporate Social Responsibility report. The Year in Review provides a comprehensive view into the company’s achievements and highlights how it has continued to deliver on its mission to improve the lives of people living with life-threatening diseases.
EJAF has announced new funding initiatives to increase advocacy and service delivery for people living with and at-risk for HIV and hepatitis C.
Funding for the new initiatives will be supported by EJAF and include financial contributions from Gilead Sciences. Gilead will also provide a donation of hepatitis C products to cure 5,000 patients – a critical contribution in a region where up to 97% of people living with HIV are co-infected with hepatitis C.
FOSTER CITY, Calif., Oct. 25, 2017 /3BL Media/ -- Gilead Sciences, Inc.(NASDAQ:GILD) announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional HIV cure research initiatives led by top academic institutions and focused on translational research and efficacy studies in preclinical models.